SEASONAL AFFECTIVE DISORDER MARKET ANALYSIS

Seasonal affective disorder (SAD) has been recognized and included in the diagnostic classification system of the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, as a major depressive disorder with seasonal pattern. Seasonality, means changing weathers highly affects people all over the world. Moreover, increasing incidence of seasonal affective disorder is expected to boost the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that around 14% of the adult in the U.S. population suffers from a lesser form of seasonal mood changes, known as winter blues.

The global seasonal affective disorder market is estimated to be valued at US$ 544.7 million in 2020 and is expected to exhibit a CAGR of 5.5% during the forecast period (2020-2027).

Figure 1. Global Seasonal Affective Disorder Market Share (%), by Region, 2020

To learn more about this report, Request sample copy

Increasing cases of seasonal affective disorder is expected to propel growth of the global seasonal affective disorder market

The increasing cases of seasonal affective disorder is expected to boost the market growth over the forecast period. For instance, according to an article published by the Royal College of Psychiatrists, in April 2015, reports that around 3 out of 100 people have significant winter depressions in the U.K.

However, side effects of seasonal affective disorder medication such as Bupropion is expected to hinder the market growth. For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in October 2020, reports that the drug Bupropion, which is approved by the U.S. FDA exhibit several side effects such as ophthalmologic including blurred vision; central nervous system including insomnia, headache, agitation, dizziness; dermatologic such as diaphoresis, and others.

Figure 2. Global Seasonal Affective Disorder Market Share (%), by Type, 2020

To learn more about this report, Request sample copy

Increasing cases of seasonal affective disorder (SAD) in North America is expected to boost the market growth

North America is expected to hold dominant position in the global seasonal affective disorder market, owing to increasing cases of seasonal affective disorder (SAD) in the region. For instance, according to an article published by the Boston University, in October 2019, reports that 10 million U.S. populace are affected by seasonal affective disorder, with women 4 times more likely to be diagnosed than men.

Global Seasonal Affective Disorder Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global seasonal affective disorder market during the forecast period.

Key Players

Major players operating in the global seasonal affective disorder market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Mylan, Inc., Bausch Health, Koninklijke Philips N.V., Bayer AG, Allergan, Bristol-Myers Squibb, and Henry Schein Inc., among others.